Trial Profile
Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Registrational; Therapeutic Use
- Acronyms PROMID
- 04 Jun 2013 Overall survival results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.